Advertisement
UK markets closed
  • FTSE 100

    8,420.26
    -18.39 (-0.22%)
     
  • FTSE 250

    20,749.90
    -72.94 (-0.35%)
     
  • AIM

    794.02
    +1.52 (+0.19%)
     
  • GBP/EUR

    1.1678
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2706
    +0.0035 (+0.28%)
     
  • Bitcoin GBP

    52,933.05
    -57.39 (-0.11%)
     
  • CMC Crypto 200

    1,369.00
    -4.84 (-0.35%)
     
  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     
  • DOW

    40,003.59
    +134.21 (+0.34%)
     
  • CRUDE OIL

    80.00
    +0.77 (+0.97%)
     
  • GOLD FUTURES

    2,419.80
    +34.30 (+1.44%)
     
  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     
  • HANG SENG

    19,553.61
    +177.08 (+0.91%)
     
  • DAX

    18,704.42
    -34.39 (-0.18%)
     
  • CAC 40

    8,167.50
    -20.99 (-0.26%)
     

Shockwave Medical Reports First Quarter 2024 Financial Results

Shockwave Medical, Inc.
Shockwave Medical, Inc.

SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.

“The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “Our team is looking forward to continuing our mission as part of Johnson & Johnson and to working together to bring our life-changing therapies to even more patients across the globe.”

First Quarter 2024 Financial Results

Revenue for the first quarter ended March 31, 2024, was $218.8 million, a 36% increase from $161.1 million in the same period of 2023. The growth in revenue was primarily driven by increased adoption of Shockwave products in both the United States and internationally.

ADVERTISEMENT

Gross profit for the first quarter of 2024 was $190.6 million compared to $140.0 million for the first quarter of 2023. Gross margin percentage was 87% for the three months ended March 31, 2024, consistent with gross margin for the three months ended March 31, 2023.

Total operating expenses for the first quarter of 2024 were $148.2 million, a 48% increase from $100.2 million in the first quarter of 2023. The increase was primarily driven by sales force expansion and higher headcount to support the growth of the business.

Net income for the first quarter of 2024 was $55.3 million, compared to net income of $39.1 million in the same period of 2023. Basic and diluted net income per share for the first quarter of 2024 was $1.48 and $1.44, respectively.

Adjusted EBITDA improved by approximately 19% to $68.5 million, in the first quarter of 2024, compared to adjusted EBITDA of $57.5 million in the first quarter of 2023. Adjusted EBITDA is a non-GAAP measure.

Cash, cash equivalents and short-term investments totaled $1,029.2 million as of March 31, 2024.

2024 Financial Guidance

Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE: JNJ), Shockwave Medical is withdrawing its full year 2024 guidance, previously issued on February 15, 2024.

Conference Call

Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE: JNJ), Shockwave Medical will not be hosting the previously scheduled earnings conference call today.

About Shockwave Medical, Inc.

Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave Medical has also recently acquired the Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com.

Forward-Looking Statements

This press release contains statements relating to our expectations, projections, beliefs, and prospects, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” and similar expressions, and the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding our pending acquisition by Johnson & Johnson, our business strategy and plans, our objectives for future operations and financial performance and other matters. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware.

If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the pending acquisition will not be satisfied, including the risk that clearance under the Hart-Scott-Rodino Antitrust Improvements Act or other applicable antitrust laws will not be obtained; uncertainty as to the percentage of our stockholders that will vote to approve the proposed transaction; the possibility that the transaction will not be completed in the expected timeframe or at all; potential adverse effects to our business or the business of Johnson & Johnson during the pendency of the transaction, such as employee departures or distraction of management from business operations; the risk of stockholder litigation relating to the transaction, including resulting expense or delay; the potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in the sections titled “Risk Factors” in our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in our other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations.

Use of Non-GAAP Financial Measures

This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP), including references to adjusted EBITDA, a non-GAAP financial measure that excludes from net income the effects of income tax (benefit) provision, other (expense) income, net, interest expense, interest income, income (loss) from equity method investment, depreciation and amortization, and stock-based compensation. We believe the presentation of adjusted EBITDA is useful as it provides visibility to our underlying continuing operating performance by excluding the impact of certain items that are non-cash in nature or not related to our core business operations.

Our definition of adjusted EBITDA may differ from similarly titled measures used by others. Adjusted EBITDA should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because adjusted EBITDA excludes the effect of items that increase or decrease our reported results of operations, management strongly encourages investors to review, when they become available, our consolidated financial statements and publicly filed reports in their entirety. A reconciliation of adjusted EBITDA to net income has been provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
dkaster@shockwavemedical.com

SHOCKWAVE MEDICAL, INC.

Balance Sheet Data

(in thousands)

 

 

 

 

 

 

 

 

March 31,
2024

 

December 31,
2023

 

 

(Unaudited)

 

 

 

ASSETS

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

Cash and cash equivalents

 

$

281,674

 

 

$

328,422

Short-term investments

 

 

747,559

 

 

 

662,132

Accounts receivable, net

 

 

124,440

 

 

 

114,552

Inventory

 

 

111,215

 

 

 

107,587

Prepaid expenses and other current assets

 

 

10,462

 

 

 

12,567

Total current assets

 

 

1,275,350

 

 

 

1,225,260

Operating lease right-of-use assets

 

 

34,919

 

 

 

29,707

Property and equipment, net

 

 

78,693

 

 

 

68,923

Equity method investment

 

 

2,356

 

 

 

1,643

Intangible assets, net

 

 

91,960

 

 

 

92,857

Goodwill

 

 

39,568

 

 

 

39,568

Deferred tax assets

 

 

111,900

 

 

 

99,169

Other assets

 

 

9,001

 

 

 

9,436

TOTAL ASSETS

 

$

1,643,747

 

 

$

1,566,563

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

Accounts payable

 

$

9,843

 

 

$

8,868

Accrued liabilities

 

 

78,838

 

 

 

91,696

Lease liability, current portion

 

 

3,653

 

 

 

3,641

Total current liabilities

 

 

92,334

 

 

 

104,205

Lease liability, noncurrent portion

 

 

40,336

 

 

 

35,103

Convertible debt, noncurrent portion

 

 

732,810

 

 

 

731,863

Related party contract liability, noncurrent portion

 

 

12,273

 

 

 

12,273

Deferred tax liabilities

 

 

3,609

 

 

 

3,609

Long-term income tax liability

 

 

2,969

 

 

 

1,526

Other liabilities

 

 

7,659

 

 

 

9,307

TOTAL LIABILITIES

 

 

891,990

 

 

 

897,886

STOCKHOLDERS’ EQUITY:

 

 

 

 

Common stock

 

 

38

 

 

 

37

Additional paid-in capital

 

 

586,017

 

 

 

557,882

Accumulated other comprehensive (loss) income

 

 

(109

)

 

 

293

Retained earnings

 

 

165,811

 

 

 

110,465

TOTAL STOCKHOLDERS’ EQUITY

 

 

751,757

 

 

 

668,677

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$

1,643,747

 

 

$

1,566,563


SHOCKWAVE MEDICAL, INC.

Statement of Operations Data

(Unaudited)

(in thousands, except share and per share data)

 

 

 

Three Months Ended

 

 

March 31,

 

 

 

2024

 

 

 

2023

 

Revenue:

 

 

 

 

Product revenue

 

$

218,805

 

 

$

161,066

 

Cost of revenue:

 

 

 

 

Cost of product revenue

 

 

28,207

 

 

 

21,066

 

Gross profit

 

 

190,598

 

 

 

140,000

 

Operating expenses:

 

 

 

 

Research and development

 

 

44,466

 

 

 

26,971

 

Sales and marketing

 

 

74,492

 

 

 

54,011

 

General and administrative

 

 

29,233

 

 

 

19,204

 

Total operating expenses

 

 

148,191

 

 

 

100,186

 

Income from operations

 

 

42,407

 

 

 

39,814

 

Income (loss) from equity method investment

 

 

713

 

 

 

(823

)

Interest income

 

 

12,318

 

 

 

1,740

 

Interest expense

 

 

(2,943

)

 

 

(636

)

Other (expense) income, net

 

 

(2,496

)

 

 

642

 

Net income before taxes

 

 

49,999

 

 

 

40,737

 

Income tax (benefit) provision

 

 

(5,347

)

 

 

1,612

 

Net income

 

$

55,346

 

 

$

39,125

 

Net income per share, basic

 

$

1.48

 

 

$

1.07

 

Net income per share, diluted

 

$

1.44

 

 

$

1.03

 

Shares used in computing net income per share, basic

 

 

37,284,946

 

 

 

36,427,263

 

Shares used in computing net income per share, diluted

 

 

38,472,013

 

 

 

37,979,448

 


SHOCKWAVE MEDICAL, INC.

Reconciliation of GAAP Net Income to Adjusted EBITDA

(Unaudited)

(in thousands)

 

 

 

Three Months Ended

 

 

March 31,

 

 

 

2024

 

 

 

2023

 

GAAP Net Income

 

$

55,346

 

 

$

39,125

 

Non-GAAP Adjustments

 

 

 

 

Income tax (benefit) provision

 

 

(5,347

)

 

 

1,612

 

Other expense (income), net

 

 

2,496

 

 

 

(642

)

Interest expense

 

 

2,943

 

 

 

636

 

Interest income

 

 

(12,318

)

 

 

(1,740

)

(Income) loss from equity method investment

 

 

(713

)

 

 

823

 

Depreciation and amortization

 

 

3,109

 

 

 

1,708

 

Stock-based compensation expense

 

 

22,937

 

 

 

15,967

 

Adjusted EBITDA

 

$

68,453

 

 

$

57,489